More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
A new analysis in Circulation: Cardiovascular Interventions examined rehospitalization rates after AVR, noting that they are consistently associated with worse outcomes and a higher risk of patient mortality.
Researchers at the Hospital for Special Surgery in New York City have demonstrated fast but fine 3D lumbar image acquisition on MRI using deep learning image reconstruction.
When resident teams included experienced fourth-year trainees, the resident/attending pairs cut overall median report turnaround times by seven minutes versus attending-only efforts.
“These results suggest that habitual checking of social media in early adolescence may be longitudinally associated with changes in neural sensitivity to anticipation of social rewards and punishments, which could have implications for psychological adjustment,” experts of a new study recently suggested.
A new study in the Journal of Nuclear Medicine offers insight into how the condition affects the general population, as well as how radiologists can help in the cardiac amyloidosis diagnostic journey.
